Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu

Last updated: July 3, 2019
Sponsor: Ache Laboratorios Farmaceuticos S.A.
Overall Status: Suspended

Phase

3

Condition

Common Cold

Acute Rhinitis

Treatment

N/A

Clinical Study ID

NCT02904304
ACH-DNT-03(02/16)
  • Ages 18-65
  • All Genders

Study Summary

National clinical trial, phase III, multicenter, randomized, prospective, double-blind, parallel, placebo-controlled, which one hundred and fifty (150) subjects of both sexes aged equal or more than 18 years will be randomly allocated to one the drug group or placebo group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age older or equal to 18 and younger than 66 years;

  • Subjects diagnosed with common cold / flu syndrome defined by clinical evaluation andthe presence of two or more of the following symptoms: sneezing, rhinorrhea, nasalobstruction, headache, throat discomfort, sore throat, dysphonia, myalgia, cough andfever classified as moderate or intense in four intensity scale (04) items (0 =absent, 01 = light, 02 = moderate, 03 = severe);

  • Beginning of the symptoms of common cold / flu-like syndrome in a minimum period of 24hours and a maximum of 72 hours prior to V0;

  • Ability to understand and consent to participate in this clinical research, expressedby signing the Informed Consent Form (ICF);

Exclusion

Exclusion Criteria:

  • Any laboratorial finding (clinical evaluation / physical evaluation / vital signs /ECG changes) that the Investigator consider a risk to subject of the study;

  • Hypersensitivity to the drug components used during the study;

  • Women in pregnancy or nursing period;

  • Women in reproductive age who do not agree to use contraception acceptable [oralcontraceptives, injectable contraceptives, intrauterine device (IUD), hormonalimplants, barrier methods, hormonal patch and tubal ligation]; other than surgicallysterile (bilateral oophorectomy or hysterectomy), postmenopausal for at least one (01)years or sexual abstinence;

  • Subjects that has participated in clinical trial protocols in the last twelve (12)months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-itemJ), unless the investigator considers that there may be a direct benefit to it;

  • Alcohol abuse that, according to the investigator, may interfere with thepharmacological adherence to the clinical protocol;

  • Any medical conditions which may interfere with efficacy and / or safety of thetreatment with the investigational product, such as but not limited to disordersdescribed below:

  • Untreated or uncontrolled Hyperthyroidism

  • Uncontrolled epilepsy

  • diagnosis of glaucoma

  • Moderate or severe persistent asthma (untreated or uncontrolled)

  • NSAID-induced asthma diagnosed

  • Systemic hypertension (SH) stage III uncontrolled

  • Moderate and severe congestive heart failure

  • Acute myocardial infarction

  • unstable angina

  • Uncontrolled cardiac arrhythmia

  • Liver failure with clinical consequences

  • Renal failure with clinical consequences

  • Diagnosed HIV positive

  • uncontrolled Diabetes type 1 or type 2

Study Design

Total Participants: 150
Study Start date:
December 01, 2020
Estimated Completion Date:
September 30, 2021

Study Description

The investigational product is a combination of desloratadine, phenylephrine hydrochloride and ibuprofen.

The desloratadine is a antihistamine and selectively block the activity of histamine receptor-1 (H1) resulting in a non sedative and prolong antiallergic effect.

The phenylephrine is a potent stimulator of the postsynaptic α receptor with minimal effect on β receptors in the heart.

The ibuprofen's mechanism is not fully known. It is a non selective inhibitor of cyclooxygenase, an enzyme that is involved in prostaglandin synthesis by the route from arachidonic acid. It is believed that the pharmacological effects are due to inhibition of cyclooxygenase-2 (COX-2), which reduces prostaglandin synthesis involved in the mediation of inflammation, pain, fever and swelling.

Connect with a study center

  • Allergisa Pesquisa Dermato Cosmética Ltda.

    Campinas, São Paulo
    Brazil

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.